首页> 外文期刊>BMC Complementary and Alternative Medicine >Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials
【24h】

Comparative efficacy of Chinese herbal injections for treating acute cerebral infarction: a network meta-analysis of randomized controlled trials

机译:中草药注射剂治疗急性脑梗死的比较疗效:随机对照试验的网络荟萃分析

获取原文
           

摘要

Chinese herbal injections (CHIs) are prepared by extracting and purifying effective substances from herbs (or decoction pieces) using modern scientific techniques and methods. CHIs combined with aspirin + anticoagulants + dehydrant + neuroprotectant (AADN) are believed to be effective for the treatment of acute cerebral infarction (ACI). However, no randomized controlled trial (RCT) has been performed to directly compare the efficacies of different regimens of CHIs. Therefore, we performed a systematic review and network meta-analysis (NMA) to compare the efficacies of different regimens of CHIs for ACI. We conducted an overall and systematic retrieval from literature databases of RCTs focused on the use of CHIs to treat ACI up to June 2016. We used the Cochrane Handbook version 5.1.0 and CONSORT statement to assess the risk of bias. The data were analyzed using STATA 13.0 and WinBUGS 1.4.3 software. Overall, 64 studies with 6225 participants involving 15 CHIs were included in the NMA. In terms of the markedly effective rate, Danhong?(DH) + AADN had the highest likelihood of being the best treatment. In terms of the improvement of neurological impairment, Shuxuening?(SXN) + AADN had the highest likelihood of being the best treatment. Considering two outcomes, injections of SXN, Yinxingdamo (YXDM), DH, Shuxuetong (SXT), HongHuaHuangSeSu (HHHSS), DengZhanXiXin (DZXX) and Shenxiong glucose (SX) plus AADN were the optimum treatment regimens for ACI, especially SXN?+?AADN and YXDM + AADN. Based on the NMA, SXN, YXDM, DH, SXT, HHHSS, DZXX and SX plus AADN showed the highest probability of being the best treatment regimens. Due to the limitations of the present study, our findings should be verified by well-designed RCTs.
机译:中草药注射剂(CHIs)是通过使用现代科学技术和方法从草药(或煎剂)中提取和纯化有效物质而制得的。 CHI联合阿司匹林+抗凝剂+脱水剂+神经保护剂(AADN)被认为可有效治疗急性脑梗死(ACI)。但是,没有进行随机对照试验(RCT)来直接比较CHIs不同治疗方案的疗效。因此,我们进行了系统的综述和网络荟萃分析(NMA),比较了不同CHI方案对ACI的疗效。我们从RCT的文献数据库中进行了全面而系统的检索,重点是截至2016年6月使用CHIs治疗ACI。我们使用了Cochrane手册5.1.0版和CONSORT声明来评估偏倚风险。使用STATA 13.0和WinBUGS 1.4.3软件分析数据。总体而言,NMA纳入了64个研究,涉及6225名参与者,涉及15个CHI。就有效率而言,丹红?(DH)+ AADN成为最佳治疗的可能性最高。就改善神经系统损伤而言,舒序宁(SXN)+ AADN成为最佳治疗方法的可能性最高。考虑到两种结果,注射SXN,银杏达摩(YXDM),DH,疏血通(SXT),红花黄素素(HHHSS),灯盏细辛(DZXX)和神雄葡萄糖(SX)加AADN是ACI的最佳治疗方案,尤其是SXN?+? AADN和YXDM + AADN。根据NMA,SXN,YXDM,DH,SXT,HHHSS,DZXX和SX加AADN显示出成为最佳治疗方案的可能性最高。由于本研究的局限性,我们的发现应通过精心设计的RCT进行验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号